C-Reactive Protein as marker for IBD
C-reactive protein (CRP) is produced by hepatocytes upon stimulation by the pro-inflammatory cytokines IL-1α, IL-6 and TNFα. It is therefore a widely used marker for inflammation and has also been shown in inflammatory bowel disease (IBD). Besides calprotectin, CRP serves as a reliable marker for the clinical course and helps to predict relapses at the onset. Literature has shown a positive correlation between CRP levels, number of relapses and severity (Koelewijn et al., 2008, World J Gastroenterol).
Quantum Blue® C-Reactive Protein (CRP)
The Quantum Blue® C-Reactive Protein (CRP) lateral flow assay is a sandwich-type immunoassay designed for the quantitative determination of CRP in human serum in combination with the BÜHLMANN Quantum Blue® reader. Less than 50 µl serum is required to perform the lateral flow test for CRP. The intended use of CRP Quantum Blue® is the monitoring of IBD with combined determination of calprotectin thereby supporting safe and accurate diagnosis as well as disease monitoring of IBD.
Quantum Blue® C-Reactive Protein (CRP) Product Information
|Time to Result
||Serum (<50 µl)
||1.0 mg/L – 25 mg/L
||Quantum Blue® Reader 2nd generation
Discontinued in May 2021
* Multilingual [EN, DE, FR, IT, ES]